BR9915512A - Análogos antagonìsticos de gh-rh que inibem igf-i e -ii - Google Patents

Análogos antagonìsticos de gh-rh que inibem igf-i e -ii

Info

Publication number
BR9915512A
BR9915512A BR9915512-5A BR9915512A BR9915512A BR 9915512 A BR9915512 A BR 9915512A BR 9915512 A BR9915512 A BR 9915512A BR 9915512 A BR9915512 A BR 9915512A
Authority
BR
Brazil
Prior art keywords
analogs
inhibit igf
inhibit
antagonistic
antagonistic analogs
Prior art date
Application number
BR9915512-5A
Other languages
English (en)
Inventor
Andrew V Schally
Jozsef Varga
Marta Zarandi
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of BR9915512A publication Critical patent/BR9915512A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"ANáLOGOS ANTAGONìSTICOS DE GH-RH QUE INIBEM IGF-I E -II" é proporcionada uma nova série de análogos sintéticos de hGH-RH (1-29)NH~ 2~. Estes análogos inibem a atividade de hGH-RH endógeno, e portanto impedem a liberação do hormónio do crescimento. As potências inibitórias mais fortes dos novos análogos, em comparação com as previamente descritas, resultam da substituição de diversos aminoácidos.
BR9915512-5A 1998-11-25 1999-11-23 Análogos antagonìsticos de gh-rh que inibem igf-i e -ii BR9915512A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/199,381 US6057422A (en) 1998-11-25 1998-11-25 Antagonistic analogs of GH-RH inhibiting IGF-I and -II
PCT/US1999/027822 WO2000031136A1 (en) 1998-11-25 1999-11-23 Antagonistic analogs of gh-rh inhibiting igf-i and -ii

Publications (1)

Publication Number Publication Date
BR9915512A true BR9915512A (pt) 2001-08-07

Family

ID=22737273

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915512-5A BR9915512A (pt) 1998-11-25 1999-11-23 Análogos antagonìsticos de gh-rh que inibem igf-i e -ii

Country Status (28)

Country Link
US (2) US6057422A (pt)
EP (1) EP1133522B1 (pt)
JP (1) JP2002530432A (pt)
KR (1) KR100629013B1 (pt)
CN (1) CN100422211C (pt)
AR (1) AR022392A1 (pt)
AT (1) ATE332310T1 (pt)
AU (1) AU757222B2 (pt)
BG (1) BG65137B1 (pt)
BR (1) BR9915512A (pt)
CA (1) CA2351665C (pt)
CO (1) CO5180565A1 (pt)
CZ (1) CZ20011794A3 (pt)
DE (1) DE69932255T2 (pt)
DK (1) DK1133522T3 (pt)
ES (1) ES2264279T3 (pt)
HU (1) HUP0105094A3 (pt)
IL (1) IL142899A0 (pt)
NO (1) NO20012489L (pt)
NZ (1) NZ511307A (pt)
PL (1) PL197471B1 (pt)
PT (1) PT1133522E (pt)
RU (1) RU2235099C2 (pt)
SK (1) SK7252001A3 (pt)
TR (1) TR200101492T2 (pt)
TW (1) TW585873B (pt)
UA (1) UA68407C2 (pt)
WO (1) WO2000031136A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454135A1 (en) * 2001-07-12 2003-01-23 Exelixis, Inc. Gpcs as modifiers of the irrtk and p21 pathways and methods of use
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
KR20050071498A (ko) * 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 성장 호르몬 방출 호르몬 유사체
TW200517400A (en) * 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
CA2718146C (en) * 2008-03-28 2016-09-20 The University Of Miami Novel n- and c-terminal substituted antagonistic analogs of gh-rh
US8691942B2 (en) 2008-03-28 2014-04-08 University Of Miami N- and C- terminal substituted antagonistic analogs of GH-RH
CN102083451A (zh) 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
CA2727082C (en) 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US8227421B2 (en) * 2009-09-17 2012-07-24 University Of Miami Fluorinated GHRH antagonists
KR20140027284A (ko) 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 성장 호르몬 방출 인자(grf) 유사체 및 이의 용도
US9079974B2 (en) * 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
WO2014100816A2 (en) 2012-12-21 2014-06-26 University Of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
US9855312B2 (en) 2012-12-21 2018-01-02 University Of Miami GHRH agonists for the treatment of ischemic disorders
WO2016077620A1 (en) 2014-11-12 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of hormonal disorders of growth
CA3129405A1 (en) 2019-02-08 2020-08-13 United States Government As Represented By The Department Of Veterans Affairs Growth hormone-releasing hormone antagonists and uses thereof
CN114126653B (zh) 2019-07-18 2024-02-20 迈阿密大学 用于治疗结节病的方法的ghrh拮抗剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659693A (en) * 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
CA2082059A1 (en) * 1990-05-04 1991-11-05 David H. Coy Synthetic grf analogs
RU2119800C1 (ru) * 1990-11-14 1998-10-10 Дзе Апджон Компани Аналог пептида фактора гормона роста (фгр), способ стимулирования секреции гормона роста и композиция для стимулирования секреции
US5550212A (en) * 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
US5942489A (en) * 1996-05-03 1999-08-24 The Administrators Of The Tulane Educational Fund HGH-RH(1-29)NH2 analogues having antagonistic activity

Also Published As

Publication number Publication date
CA2351665A1 (en) 2000-06-02
US7026281B1 (en) 2006-04-11
NZ511307A (en) 2005-01-28
CN1328570A (zh) 2001-12-26
PT1133522E (pt) 2006-11-30
PL349877A1 (en) 2002-09-23
BG105638A (en) 2002-01-31
UA68407C2 (en) 2004-08-16
WO2000031136A1 (en) 2000-06-02
IL142899A0 (en) 2002-04-21
CA2351665C (en) 2008-09-02
KR20010101079A (ko) 2001-11-14
TR200101492T2 (tr) 2001-11-21
DE69932255T2 (de) 2007-05-31
WO2000031136A9 (en) 2001-07-19
DE69932255D1 (de) 2006-08-17
RU2235099C2 (ru) 2004-08-27
ATE332310T1 (de) 2006-07-15
TW585873B (en) 2004-05-01
HK1036461A1 (en) 2002-01-04
HUP0105094A3 (en) 2002-05-28
AR022392A1 (es) 2002-09-04
DK1133522T3 (da) 2006-11-06
HUP0105094A2 (hu) 2002-04-29
SK7252001A3 (en) 2002-02-05
NO20012489L (no) 2001-07-04
BG65137B1 (bg) 2007-03-30
CZ20011794A3 (cs) 2002-02-13
US6057422A (en) 2000-05-02
CO5180565A1 (es) 2002-07-30
PL197471B1 (pl) 2008-04-30
NO20012489D0 (no) 2001-05-21
JP2002530432A (ja) 2002-09-17
KR100629013B1 (ko) 2006-09-26
ES2264279T3 (es) 2006-12-16
AU757222B2 (en) 2003-02-06
EP1133522A1 (en) 2001-09-19
CN100422211C (zh) 2008-10-01
AU2029100A (en) 2000-06-13
EP1133522B1 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
BR9915512A (pt) Análogos antagonìsticos de gh-rh que inibem igf-i e -ii
FI940807A0 (fi) Peptidejä, joilla on kasvuhormonia vapauttavaa aktiivisuutta
IL118330A0 (en) Dipeptides which promote release of growth hormone
EP0528312A3 (en) Cyclic peptides and use thereof
DE69836386D1 (de) Amide zur Förderung der Ausschüttung von Wachstumshormonen
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE3381282D1 (de) Peptidverbindungen.
SE9101838D0 (sv) Novel peptides and their use
ES2012720A6 (es) Procedimiento para la obtencion de sales de adicion de acido de taurina o glicina amidada.
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
MX9702275A (es) Compuestos polipectidicos que contienen d-2 alquiltriptofano capaces de promover la liberacion de hormona del crecimiento.
ES2135398T3 (es) Compuesto y composiciones de inhibicion de la resorcion osea.
MY114428A (en) New pharmacological use of aii-receptor antagonists
KR950703347A (ko) 이노시톨 1,4,5-트리포스페이트의 길항 방법(Method for Antagonizing Inositol 1,4,5-Triphosphate)
DE69619530D1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
BR9611760A (pt) Novos antagonistas lh-rh com efeito aperfeiçoado
DE69119409D1 (de) Vasoaktive derivate des vasotocins
SE9802538D0 (sv) New pharmaceutically active compounds
EA199900551A1 (ru) Фармацевтическая композиция, содержащая ингибитор иммуноглобулин-рецепторного взаимодействия
FI933231A0 (fi) Acylaminoalkylidenhydroxibisfosfonsyror anvaendningsbara vid terapi av benledsjukdomar
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
ATE70454T1 (de) Vincristin enthaltendes produkt.
ES8800271A1 (es) Un procedimiento para preparar heptapeptidos ciclicos basicos y aromaticos.
MX9701526A (es) Terapia combinada para tratar la osteoporosis.
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements